Federal Hemp Restrictions: Compliance Guide for Cannabis Businesses

Executive Summary

Federal hemp restrictions represent the most significant regulatory upheaval for the cannabis industry since the 2018 Farm Bill legalized hemp cultivation, with new USDA rules, DEA enforcement priorities, and FDA oversight converging to reshape a market that generated $28.4 billion in retail sales in 2025. The regulatory framework governing hemp—defined as cannabis containing 0.3% or less delta-9 THC by dry weight—has fractured into a complex patchwork of federal enforcement actions, state-level bans, and industry compliance challenges. In September 2026, Congress extended implementation deadlines for major restrictions by one month, providing temporary relief but no long-term clarity for operators navigating intoxicating hemp cannabinoid products, testing protocols, and interstate commerce rules. The restrictions affect every segment of the hemp supply chain, from farmers facing new USDA testing requirements to retailers selling delta-8 THC products under threat of DEA enforcement. Understanding these restrictions is essential for cannabis operators, investors, policymakers, and consumers as the legal boundary between hemp and marijuana continues to shift.

Why Federal Hemp Restrictions Matter

The federal hemp regulatory landscape directly impacts 54,000 licensed hemp farmers, 17,200 registered hemp processors, and an estimated 35,000 retail locations selling hemp-derived products across the United States. The 2018 Farm Bill removed hemp from Schedule I of the Controlled Substances Act, creating a legal pathway for hemp cultivation and commerce that generated $824 million in farm-gate revenue in 2025 according to USDA data. However, the emergence of intoxicating hemp-derived cannabinoids—including delta-8 THC, delta-10 THC, THC-O, and THCP—created regulatory gaps that federal agencies are now closing through coordinated enforcement. The financial stakes are substantial. Hemp-derived CBD products alone accounted for $6.4 billion in sales in 2025, while intoxicating hemp cannabinoids generated an estimated $2.8 billion in retail sales before state-level restrictions began taking effect. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries have invested heavily in hemp-derived product lines as federally compliant alternatives to state-licensed marijuana products. The September 2026 deadline extension affects product formulations, supply chain logistics, and capital allocation decisions across the industry. For patients and consumers, federal hemp restrictions determine product availability, testing standards, and legal protections. An estimated 14 million Americans regularly use hemp-derived CBD products for conditions including chronic pain, anxiety, and sleep disorders, according to survey data from the National Institutes of Health. The restrictions also affect military service members, federal employees, and individuals in states without legal marijuana programs who rely on hemp products as their only legal access to cannabinoids.

Background and History: From Farm Bill to Federal Crackdown

The modern federal hemp regulatory framework emerged from the Agricultural Improvement Act of 2018, but the legal distinction between hemp and marijuana traces back to the Controlled Substances Act of 1970.

The Controlled Substances Act and Early Hemp Prohibition (1970-2014)

When Congress passed the Controlled Substances Act in 1970, the statute defined marijuana as "all parts of the plant Cannabis sativa L." without distinguishing between intoxicating and non-intoxicating varieties. This classification effectively prohibited hemp cultivation alongside marijuana, despite hemp's historical use for fiber, seed, and industrial applications. The DEA interpreted 21 U.S.C. § 812 to include all cannabis plants regardless of THC content, creating a blanket prohibition that lasted four decades. The 2014 Farm Bill created the first modern exception through its Hemp Pilot Program, allowing state agriculture departments and research institutions to cultivate hemp for research purposes. Section 7606 of the Agricultural Act of 2014 defined hemp as cannabis containing "not more than 0.3 percent concentration of delta-9 tetrahydrocannabinol on a dry weight basis." This threshold, originally proposed by Canadian scientist Ernest Small in a 1976 taxonomy paper, became the legal dividing line between hemp and marijuana despite limited scientific basis for the specific percentage.

The 2018 Farm Bill and Hemp Legalization (2018-2019)

The Agricultural Improvement Act of 2018, signed into law on December 20, 2018, fundamentally changed hemp's legal status. Section 10113 removed hemp from Schedule I of the Controlled Substances Act, explicitly defining hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." The 2018 Farm Bill assigned regulatory authority to three federal agencies. The USDA received jurisdiction over hemp cultivation and production through 7 U.S.C. § 1639o, requiring the agency to establish a national regulatory framework. The FDA retained authority over hemp-derived products intended for human or animal consumption under the Federal Food, Drug, and Cosmetic Act. The DEA maintained enforcement authority over cannabis exceeding the 0.3% delta-9 THC threshold.

USDA Hemp Production Rules (2019-2021)

On October 31, 2019, the USDA published its interim final rule establishing the U.S. Domestic Hemp Production Program. The rule required states and tribal nations to submit hemp production plans for USDA approval, established testing protocols requiring laboratories to use post-decarboxylation methods measuring total THC, and created compliance procedures for plants testing above 0.3% THC. The USDA received more than 4,500 public comments on the interim rule, with farmers and processors objecting to testing requirements they characterized as overly stringent. The USDA published its final rule on January 19, 2021, maintaining most provisions from the interim rule but extending the compliance timeline. As of September 2026, all 50 states and four tribal nations operate USDA-approved hemp production plans, with 54,239 licensed hemp producers cultivating 53,419 acres according to USDA data.

The Rise of Intoxicating Hemp Cannabinoids (2019-2024)

The 2018 Farm Bill's focus on delta-9 THC concentration created an unintended loophole. Manufacturers discovered they could convert CBD derived from legal hemp into delta-8 THC, delta-10 THC, and other intoxicating cannabinoids through chemical processes. These semi-synthetic cannabinoids produced psychoactive effects similar to delta-9 THC found in marijuana but remained technically legal under the Farm Bill's definition because the source material contained less than 0.3% delta-9 THC. Delta-8 THC products appeared in gas stations, convenience stores, and online retailers starting in 2019, growing into a $2 billion market by 2023. The products existed in a regulatory gray area—legal under a literal reading of the 2018 Farm Bill but potentially prohibited under the Federal Analogue Act or FDA enforcement authority.

DEA Interim Final Rule on Hemp Regulations (2020)

On August 21, 2020, the DEA published an interim final rule implementing the 2018 Farm Bill's hemp provisions. The rule clarified that "synthetically derived tetrahydrocannabinols remain schedule I controlled substances" under 21 CFR § 1308.11(d)(31). The DEA stated that "for synthetically derived tetrahydrocannabinols, the concentration of delta-9 THC is not a determining factor in whether the material is a controlled substance." This language created ambiguity about delta-8 THC and similar cannabinoids. Industry advocates argued these compounds were naturally occurring cannabinoids extracted from legal hemp, while the DEA maintained they were synthetic controlled substances when produced through chemical conversion processes.

State-Level Restrictions and Enforcement Actions (2021-2025)

As intoxicating hemp products proliferated, states began implementing restrictions. Alaska banned delta-8 THC products in July 2021, followed by Colorado, Oregon, and 15 other states by the end of 2023. These state-level bans created a fragmented market where products legal in Tennessee faced criminal penalties in neighboring Kentucky. The FDA issued warning letters to companies making unsubstantiated health claims about CBD products, sending 190 warning letters between 2019 and 2025. However, the agency declined to establish a comprehensive regulatory framework for hemp-derived products, citing resource constraints and competing priorities.

The 2024 Farm Bill Debate and Hemp Restrictions (2024-2025)

Reauthorization of the Farm Bill, originally scheduled for 2023, became the focal point for hemp regulation debates. The House Agriculture Committee's draft bill included provisions to ban intoxicating hemp cannabinoids, restrict THC concentration limits to 0.3% for all THC isomers (not just delta-9), and impose new testing and labeling requirements. The Senate Agriculture Committee proposed alternative language focusing on FDA regulatory authority rather than outright bans. Congress failed to pass a comprehensive Farm Bill reauthorization in 2024, instead approving a series of continuing resolutions extending 2018 Farm Bill provisions. This legislative stalemate left hemp operators without clarity about future regulations while federal agencies prepared enforcement actions under existing authority.

Federal Enforcement Escalation (2025-2026)

In March 2025, the DEA announced Operation Hemp Sweep, a coordinated enforcement initiative targeting manufacturers and retailers of intoxicating hemp products. The agency executed search warrants at 47 locations across 12 states, seizing products and records. The DEA characterized delta-8 THC and similar products as controlled substance analogues subject to criminal penalties under 21 U.S.C. § 813. The USDA simultaneously announced enhanced testing requirements for hemp crops, requiring laboratories to test for total THC (including delta-8, delta-10, and other isomers) rather than delta-9 THC alone. The new testing protocols, scheduled to take effect October 1, 2026, would render many hemp genetics non-compliant and require farmers to destroy crops testing above the threshold.

The September 2026 Deadline Extension

On September 8, 2026, Congress passed a one-month extension of the implementation deadline for new federal hemp restrictions, moving the effective date from October 1, 2026 to November 1, 2026. The extension came as part of a broader continuing resolution funding federal agencies through December 2026. Lawmakers provided no additional guidance about long-term hemp policy, leaving operators with 30 additional days but no additional certainty about regulatory direction.

Key Players in Federal Hemp Regulation

Federal hemp restrictions involve multiple agencies with overlapping jurisdiction, creating coordination challenges and regulatory gaps.

U.S. Department of Agriculture

The USDA's Agricultural Marketing Service administers the U.S. Domestic Hemp Production Program under authority granted by 7 U.S.C. § 1639o. The agency approves state and tribal hemp production plans, licenses hemp producers in states without approved plans, and establishes testing protocols for THC concentration. USDA Administrator Jenny Lester Moffitt oversees hemp policy implementation, working with state agriculture commissioners to enforce compliance requirements. The USDA's September 2026 guidance expanded testing requirements to include all THC isomers, not just delta-9 THC, fundamentally changing compliance standards for farmers.

Drug Enforcement Administration

The DEA maintains enforcement authority over cannabis products exceeding 0.3% THC and synthetic cannabinoids under the Controlled Substances Act. DEA Administrator Anne Milgram has prioritized enforcement against intoxicating hemp products, characterizing them as controlled substance analogues. The agency's Diversion Control Division conducts investigations, executes search warrants, and coordinates with U.S. Attorneys' offices on criminal prosecutions. The DEA's position that chemically converted cannabinoids constitute synthetic controlled substances regardless of source material creates legal uncertainty for manufacturers using isomerization processes.

Food and Drug Administration

The FDA regulates hemp-derived products intended for human or animal consumption under the Federal Food, Drug, and Cosmetic Act. The agency has authority to establish safety standards, testing requirements, and labeling rules but has declined to create a comprehensive regulatory framework for CBD or other hemp cannabinoids. FDA Commissioner Robert Califf has stated the agency lacks resources to regulate the hemp-derived product market effectively, calling on Congress to provide additional statutory authority and funding. The FDA's enforcement focuses on companies making disease treatment claims or selling products with contaminants, issuing warning letters rather than pursuing criminal enforcement.

Hemp Industry Associations

The U.S. Hemp Roundtable, Vote Hemp, and National Hemp Association represent hemp farmers, processors, and retailers in policy advocacy. These organizations have lobbied for regulatory clarity while opposing outright bans on intoxicating hemp products. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, has argued that federal restrictions should focus on product safety and age restrictions rather than prohibition. The industry associations supported the September 2026 deadline extension, characterizing it as an opportunity for Congress to develop comprehensive hemp policy rather than implementing restrictions through agency enforcement.

State Regulators and the Cannabis Control Boards

State cannabis control boards in California, Colorado, Michigan, and other jurisdictions with legal marijuana programs have implemented restrictions on intoxicating hemp products to protect state-licensed marijuana markets. These regulators argue that delta-8 THC and similar products create an unregulated parallel market undermining state testing, taxation, and licensing requirements. The National Cannabis Industry Association has supported federal restrictions on intoxicating hemp cannabinoids, viewing them as competition for state-licensed operators.

Multi-State Operators and Hemp Companies

Companies including Curaleaf, Charlotte's Web, and cbdMD have invested hundreds of millions of dollars in hemp-derived product lines. These operators face strategic decisions about product portfolios, supply chain investments, and market positioning as federal restrictions evolve. Curaleaf CEO Matt Darin has stated the company is prepared to reformulate products to comply with new federal standards while maintaining market presence. Smaller hemp companies lack the capital and regulatory expertise to navigate changing requirements, creating consolidation pressure in the industry.

Legal and Regulatory Framework

Federal hemp restrictions operate through a complex interaction of statutes, agency rules, and enforcement policies spanning agriculture, drug control, and consumer protection law. The Agricultural Improvement Act of 2018, codified at 7 U.S.C. § 1639o through § 1639s, provides the statutory foundation for hemp regulation. Section 297A defines hemp as cannabis containing "not more than 0.3 percent concentration of delta-9 tetrahydrocannabinol on a dry weight basis." This definition explicitly includes "all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers" derived from compliant hemp plants. The Controlled Substances Act, 21 U.S.C. § 801 et seq., establishes federal drug control authority. Section 802(16) defines marijuana as "all parts of the plant Cannabis sativa L." but excludes hemp as defined in 7 U.S.C. § 1639o. However, Section 813 grants the DEA authority to temporarily schedule substances that are "substantially similar" to Schedule I or II controlled substances, creating the legal basis for enforcement against synthetic cannabinoids. The Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., grants the FDA authority to regulate food, drugs, and dietary supplements. Section 331(ll) prohibits introducing food containing CBD into interstate commerce, though the FDA has exercised enforcement discretion and not pursued systematic enforcement of this prohibition. USDA regulations at 7 CFR Part 990 establish the U.S. Domestic Hemp Production Program, requiring hemp producers to obtain licenses, submit to inspections, and test crops within 15 days of harvest using DEA-registered laboratories. The regulations specify that testing must measure total THC using post-decarboxylation methods, converting THCA to THC through heating to determine total potential THC content. DEA regulations at 21 CFR § 1308.11 list controlled substances by schedule. The August 2020 interim final rule clarified that "synthetically derived tetrahydrocannabinols remain schedule I controlled substances" regardless of source material. This regulatory language creates ambiguity about cannabinoids produced through chemical conversion of CBD extracted from legal hemp. The Federal Analogue Act, 21 U.S.C. § 813, allows the DEA to treat substances "substantially similar" to Schedule I or II drugs as controlled substances for prosecution purposes. The DEA has cited this authority in enforcement actions against delta-8 THC and THC-O products, arguing these cannabinoids are analogues of delta-9 THC.

State-by-State Hemp Restrictions

State-level hemp regulations create a fragmented legal landscape where products legal in one jurisdiction face criminal penalties across state lines.

Alaska

Alaska banned delta-8 THC and other intoxicating hemp-derived cannabinoids in July 2021 through emergency regulations adopted by the Alaska Marijuana Control Board. The state defines any psychoactive cannabinoid as marijuana subject to state licensing requirements, regardless of source material. Possession limits for legal marijuana in Alaska are one ounce for adults 21 and older, with hemp-derived intoxicating products treated identically to marijuana for enforcement purposes.

California

California implemented Assembly Bill 45 in October 2023, prohibiting the sale of intoxicating hemp products outside the state's licensed marijuana market. The law requires all hemp products containing detectable amounts of THC to be sold through licensed cannabis retailers subject to testing, taxation, and age verification requirements. California allows adults 21 and older to possess up to one ounce of cannabis, with hemp-derived THC products counting toward this limit.

Colorado

Colorado banned delta-8 THC, delta-10 THC, and THC-O products in September 2021, with the Colorado Department of Public Health and Environment characterizing these substances as controlled substances requiring state licensing. The state's Marijuana Enforcement Division treats hemp-derived intoxicating cannabinoids as marijuana for regulatory purposes. Colorado allows adults 21 and older to possess up to two ounces of marijuana, with hemp-derived products subject to the same limits.

Florida

Florida permits hemp-derived CBD products but has not implemented comprehensive restrictions on intoxicating hemp cannabinoids as of September 2026. The Florida Department of Agriculture and Consumer Services regulates hemp cultivation under a USDA-approved plan, while the Florida Department of Health oversees medical marijuana licensing. The state's legal framework creates ambiguity about delta-8 THC products, which remain available at retail despite lacking explicit authorization.

Kentucky

Kentucky banned intoxicating hemp products in March 2023 through House Bill 829, requiring all psychoactive cannabinoids to be sold through the state's medical marijuana program scheduled to launch in 2027. The law defines intoxicating hemp products as those containing "a total delta-9 tetrahydrocannabinol concentration of more than 0.3 percent" or "any amount of synthetically derived cannabinoids." Kentucky does not allow adult-use marijuana, limiting legal cannabis access to medical patients.

Michigan

Michigan implemented restrictions on intoxicating hemp products in November 2024, requiring these products to be sold through state-licensed marijuana retailers. The Michigan Marijuana Regulatory Agency treats hemp-derived delta-8 THC and similar cannabinoids as marijuana for regulatory purposes. Michigan allows adults 21 and older to possess up to 2.5 ounces of marijuana, with hemp-derived products subject to identical limits and testing requirements.

New York

New York banned the sale of intoxicating hemp products outside licensed cannabis retailers in September 2023. The state's Office of Cannabis Management requires all products containing THC, regardless of source, to undergo testing for potency, pesticides, heavy metals, and microbial contaminants. New York allows adults 21 and older to possess up to three ounces of cannabis, with hemp-derived products counting toward this limit.

Ohio

Ohio permits hemp-derived CBD products under its USDA-approved hemp program but has not implemented comprehensive restrictions on intoxicating hemp cannabinoids. The Ohio Department of Agriculture regulates hemp cultivation, while the State Board of Pharmacy oversees medical marijuana licensing. Voters approved adult-use marijuana legalization in November 2023, with implementation ongoing as of September 2026. The state's regulatory framework does not explicitly address delta-8 THC and similar hemp-derived products.

Oregon

Oregon banned intoxicating hemp products in June 2022, requiring all psychoactive cannabinoids to be sold through the state's licensed marijuana market. The Oregon Liquor and Cannabis Commission treats artificially derived cannabinoids as marijuana for regulatory purposes. Oregon allows adults 21 and older to possess up to two ounces of marijuana, with hemp-derived products subject to identical limits.

Texas

Texas permits hemp-derived products containing less than 0.3% delta-9 THC under its USDA-approved hemp program, creating one of the largest markets for delta-8 THC and similar products. The Texas Department of State Health Services regulates hemp processing and manufacturing, while the Texas Department of Agriculture oversees cultivation. Texas does not allow adult-use or comprehensive medical marijuana, making hemp-derived products the primary legal source of THC for most residents. State lawmakers have debated restrictions on intoxicating hemp products but have not enacted comprehensive bans as of September 2026.

Market and Business Implications

Federal hemp restrictions are forcing strategic realignment across the cannabis industry, affecting capital allocation, product development, and competitive positioning. The hemp-derived CBD market generated $6.4 billion in retail sales in 2025, with products sold through 35,000 retail locations including grocery stores, pharmacies, and specialty retailers. Federal restrictions on intoxicating hemp cannabinoids threaten to eliminate an estimated $2.8 billion market segment, forcing companies to reformulate products or exit the category entirely. Multi-state operators face decisions about hemp-derived product lines. Curaleaf invested $286 million acquiring hemp CBD brands including Select and FOCUS, positioning hemp products as federally compliant alternatives to state-licensed marijuana. The company's hemp segment generated $127 million in revenue in 2025, representing 8% of total sales. Federal restrictions requiring hemp products to contain zero intoxicating cannabinoids would force reformulation of product lines and potentially strand inventory. Trulieve acquired Harvest Health & Recreation in 2021 for $2.1 billion, gaining access to hemp cultivation and processing assets. The company has invested in hemp-derived product development as a hedge against state-level regulatory changes. Federal restrictions on intoxicating hemp products reduce the strategic value of these assets, potentially requiring asset write-downs. Green Thumb Industries has avoided significant hemp investments, focusing exclusively on state-licensed marijuana markets. CEO Ben Kovler has characterized intoxicating hemp products as regulatory arbitrage that undermines state licensing systems. Federal restrictions eliminating intoxicating hemp products would benefit state-licensed operators by reducing competition from unregulated products sold outside licensed channels. Wholesale hemp biomass pricing reflects regulatory uncertainty. CBD-rich hemp biomass traded at $0.42 per percentage point of CBD per pound in September 2026, down from $0.68 in September 2025. Farmers cultivating hemp for CBD extraction face margin pressure as oversupply and regulatory uncertainty depress prices. The USDA reported 53,419 acres of hemp cultivation in 2026, down from 67,240 acres in 2024, reflecting reduced farmer interest amid market volatility. Hemp-derived product manufacturers face compliance costs for testing, reformulation, and regulatory navigation. Third-party testing for potency, pesticides, heavy metals, and microbial contaminants costs $400 to $800 per batch, with manufacturers testing multiple batches to ensure compliance. Reformulation costs to eliminate intoxicating cannabinoids range from $50,000 to $200,000 per product line, including stability testing and shelf-life studies. Capital markets have reduced funding for hemp companies amid regulatory uncertainty. Venture capital investment in hemp and CBD companies totaled $247 million in 2025, down from $512 million in 2023. Public market valuations for hemp-focused companies declined an average of 43% from January 2025 to September 2026 as investors priced in regulatory risk.

What Experts Say About Federal Hemp Restrictions

Industry stakeholders, legal experts, and policymakers offer divergent perspectives on federal hemp restrictions, reflecting fundamental disagreements about regulatory philosophy and market structure. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, has argued that federal restrictions should focus on product safety rather than prohibition. According to Miller, the 2018 Farm Bill created a legal hemp market that has generated economic opportunity for farmers and provided consumers access to cannabinoid products. Miller has stated that appropriate regulation would establish testing standards, age restrictions, and labeling requirements while preserving market access for compliant products. Shawn Hauser, partner at Vicente Sederberg LLP and hemp regulatory specialist, has characterized the current federal approach as creating legal uncertainty that harms compliant businesses. According to Hauser, the DEA's position that chemically converted cannabinoids constitute synthetic controlled substances lacks clear statutory basis and contradicts the 2018 Farm Bill's broad definition of hemp derivatives. Hauser has advocated for congressional action to clarify the legal status of hemp-derived cannabinoids produced through chemical processes. Rod Kight, cannabis attorney and hemp law specialist, has argued that delta-8 THC and similar cannabinoids are legal under a plain reading of the 2018 Farm Bill. According to Kight, the statute's definition of hemp includes "all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers" from compliant hemp plants, without restricting chemical processes used to produce these compounds. Kight has stated that federal enforcement actions against hemp-derived products exceed agency authority and should be challenged in court. The National Cannabis Industry Association, representing state-licensed marijuana operators, has supported federal restrictions on intoxicating hemp products. According to the organization, delta-8 THC and similar products create an unregulated market that undermines state testing, taxation, and licensing requirements. The association has argued that all intoxicating cannabis products should be subject to state regulatory oversight regardless of source material. Shane Pennington, counsel at Vicente Sederberg LLP specializing in hemp regulatory issues, has stated that the September 2026 deadline extension provides temporary relief but does not resolve fundamental legal questions about hemp-derived cannabinoids. According to Pennington, companies should use the additional time to evaluate product portfolios, assess regulatory risk, and develop contingency plans for multiple regulatory scenarios. Douglas Berman, professor at Ohio State University Moritz College of Law and drug policy expert, has characterized federal hemp restrictions as reflecting broader tensions in cannabis federalism. According to Berman, the 2018 Farm Bill created a legal framework that conflicts with the Controlled Substances Act's prohibition on intoxicating cannabis products, forcing agencies to reconcile contradictory statutory mandates. Berman has stated that comprehensive congressional action is necessary to resolve these conflicts and establish coherent federal cannabis policy.

What's Next: Timeline and Scenarios

The November 1, 2026 implementation deadline for new federal hemp restrictions creates immediate compliance requirements, while longer-term policy remains uncertain pending congressional action. The immediate timeline includes several key dates. On November 1, 2026, new USDA testing requirements take effect, requiring laboratories to test for total THC including all isomers rather than delta-9 THC alone. This change will render many hemp genetics non-compliant, requiring farmers to destroy crops testing above 0.3% total THC. The DEA has indicated it will intensify enforcement against intoxicating hemp products after November 1, with additional search warrants and seizures planned. Congress faces a December 2026 deadline to pass a comprehensive Farm Bill reauthorization or approve another continuing resolution. The House Agriculture Committee has proposed language banning intoxicating hemp cannabinoids and restricting THC limits to 0.3% for all isomers. The Senate Agriculture Committee has proposed alternative language directing the FDA to establish a regulatory framework for hemp-derived products within 18 months. Reconciling these approaches will determine the long-term federal hemp policy framework. Industry observers identify three primary scenarios for federal hemp regulation. In a restrictive scenario, Congress bans intoxicating hemp cannabinoids entirely, limiting legal hemp products to those containing zero psychoactive compounds. This outcome would eliminate the delta-8 THC market, force product reformulations, and benefit state-licensed marijuana operators by reducing competition. The restrictive scenario appears most likely based on current congressional proposals and agency enforcement priorities. In a moderate scenario, Congress establishes a regulated market for hemp-derived cannabinoids with testing requirements, potency limits, and age restrictions but preserves legal access to intoxicating products. This outcome would require FDA regulatory framework development, potentially taking several years to implement. The moderate scenario would preserve hemp market opportunities while addressing safety concerns through product standards. In a permissive scenario, Congress maintains the 2018 Farm Bill framework with minimal additional restrictions, allowing states to regulate hemp-derived products according to local preferences. This outcome appears least likely given bipartisan congressional support for federal restrictions and agency enforcement priorities. Companies should establish trigger points for strategic decisions based on regulatory developments. If Congress passes comprehensive hemp restrictions in December 2026, operators should immediately evaluate product portfolios and begin reformulation processes. If Congress approves another continuing resolution without policy clarity, companies should prepare for extended regulatory uncertainty and potential agency enforcement actions. The FDA's role remains uncertain. If Congress directs the agency to establish hemp product regulations, the rulemaking process will likely take 18 to 36 months, including public comment periods and scientific review. The FDA has indicated it would prioritize safety standards, testing requirements, and labeling rules, potentially creating a pathway for regulated hemp-derived cannabinoid products. State-level policy will continue evolving regardless of federal action. Additional states are likely to implement restrictions on intoxicating hemp products, particularly those with legal marijuana markets seeking to protect state-licensed operators. Operators should monitor state legislative sessions in California, Florida, Texas, and other major markets for proposed hemp restrictions.

Further Reading and Primary Sources

• Agricultural Improvement Act of 2018, Public Law 115-334, full text available at https://www.congress.gov/bill/115th-congress/house-bill/2
• USDA U.S. Domestic Hemp Production Program, 7 CFR Part 990, available at https://www.ams.usda.gov/rules-regulations/hemp
• DEA Implementation of the Agriculture Improvement Act of 2018, Interim Final Rule, 85 FR 51639, available at https://www.federalregister.gov/documents/2020/08/21/2020-18455
• Controlled Substances Act, 21 U.S.C. § 801 et seq., available at https://www.dea.gov/drug-information/csa
• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., available at https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act
• USDA Hemp Production Data and Statistics, available at https://www.nass.usda.gov/Surveys/Guide_to_NASS_Surveys/Hemp/
• U.S. Hemp Roundtable policy resources and regulatory updates, available at https://www.hempsupporter.com
• Vote Hemp industry reports and state hemp program information, available at https://www.votehemp.com
• FDA Cannabis and Cannabis-Derived Compounds information page, available at https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products
• Congressional Research Service, "The 2018 Farm Bill and Hemp Production," available at https://crsreports.congress.gov
• National Conference of State Legislatures hemp legislation database, available at https://www.ncsl.org/agriculture-and-rural-development/state-industrial-hemp-statutes

Update — September 30, 2026: Wisconsin Hemp Retailers Report Closure Risk Under New Federal Rules

Hemp and CBD retailers in Wisconsin said new federal restrictions threaten their ability to remain operational, according to interviews conducted by WEAU. Multiple business owners reported that compliance costs associated with recently implemented federal hemp regulations could force store closures within 90 days. The restrictions affect product testing requirements, labeling standards, and distribution chain documentation for hemp-derived cannabinoid products sold at retail.

Small-scale operators face disproportionate compliance burdens compared to vertically integrated companies, according to business owners interviewed. Independent retailers must now verify third-party lab testing for every product batch and maintain chain-of-custody documentation traceable to registered hemp cultivators. One store owner said the administrative overhead alone requires hiring additional staff, while testing fees add $200 to $500 per product SKU quarterly.

The operational impact extends beyond direct compliance costs. Retailers reported losing access to wholesale suppliers who cannot meet the new federal documentation standards, forcing inventory reductions of 40% to 60% in some stores. Payment processors have also increased scrutiny of hemp transactions, with several businesses reporting frozen accounts pending additional compliance verification.

Wisconsin hemp retailers operate under both the 2018 Farm Bill framework and state-specific regulations adopted in 2020. The new federal requirements create a compliance gap for businesses that previously relied on state-level oversight alone. Industry representatives told WEAU they are seeking clarification from the U.S. Department of Agriculture on transition timelines and small business exemptions. The financial pressure arrives as Wisconsin's hemp retail sector employed approximately 2,400 workers across 340 licensed locations as of June 2026, according to state licensing data.